Human Immunodeficiency Virus HIV CD3+ T Cells
About: Human Immunodeficiency Virus HIV CD3 T Cells are isolated from IRB-consented HIV-positive donors. Useful for assessing T cell exhaustion, viral persistence, and immune dysregulation in chronic HIV infection.
Human Immunodeficiency Virus HIV CD3 T Cells for Autoimmune and Immunopathology Research
Human Immunodeficiency Virus HIV CD3 T Cells are isolated from peripheral blood of IRB-consented adult donors diagnosed with Human Immunodeficiency Virus HIV. These CD3+ T lymphocytes reflect the immune dysfunction associated with HIV and are valuable for investigating T cell phenotypes, cytokine secretion, exhaustion, and inflammation in autoimmunity and chronic disease.
Product Features
- Research Use Only (RUO), CD3+ enriched T cells
- Isolated from clinically confirmed HIV donors
- High viability and CD3+ cell enrichment
- Cryopreserved in CryoStor® CS10 media
- Processed within 24 hours of collection
- IRB-approved collection and HIPAA-compliant handling
De-identified Donor Data
- Confirmed HIV diagnosis
- Demographics: age, sex assigned at birth, race/ethnicity
- Clinical history and medication records available
Applications
- T cell subset analysis and immune profiling in HIV
- Autoimmunity, exhaustion, and cytokine production studies
- Target validation and preclinical drug development
- Cell therapy and immune modulation modeling
Compliance and Quality Assurance
- IRB-approved protocols and 21 CFR Part 11–compliant e-consent
- Standardized isolation and cryopreservation
- HIPAA-compliant data protection and donor confidentiality
Ordering & Customization
Human Immunodeficiency Virus HIV CD3 T Cells are available in standard or custom aliquot sizes. For international shipments or documentation, contact learnmore@sanguinebio.com.
Protocols & Documentation
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
HIV Publications
CD3+ T Cells
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – with the exception of GMP leukopaks, all our products are research use only (RUO).
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom CD3+ T Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.